The Epidermal Growth Factor Receptor (EGFR) and KRAS, two pivotal components of RTK-ERK signaling pathways, are the most frequent targets for oncogenic driver mutations in lung adenocarcinoma (LUAD). This evidence concerns the gene EGFR and lung adenocarcinoma.